NCI ID NCI-2020-02360
NCT ID NCT04455750
CTEP ID A031902
Primary Purpose TREATMENT
Anatomic Sites Prostate
Minimum Age 18 Years
Maximum Age 999 Years
Gender MALE
Lead Org Alliance for Clinical Trials in Oncology
Principal Investigator Arpit Rao
NCI Site View on

CASPAR, A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men with Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

This phase III trial compares the addition of rucaparib to enzalutamide with enzalutamide alone for the treatment of men with prostate cancer that has spread to other places in the body (metastatic) and has become resistant to androgen-deprivation therapy. Testosterone is a hormone made mainly in the testes and is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. It also plays role in prostate cancer development. Enzalutamide may help fight prostate cancer by blocking the use of testosterone by the tumor cells for growth. PARPs are proteins that help repair deoxyribonucleic acid (DNA) mutations. PARP inhibitors, such as rucaparib, can keep PARPs from working, so tumor cells can't repair themselves. This may stop tumor cells from growing. Giving enzalutamide and rucaparib may prolong patients’ survival and/or prevent their cancer from growing or spreading for a longer time. It may also help doctors learn if a mutation in any of the specific DNA repair (homologous recombination) genes is helpful in selecting the most appropriate treatment for the patient.


Inclusion Criterea

  • Histologic/cytologic documentation of prostate adenocarcinoma
  • Adequate archival tumor specimen or archival slides must be available to be tested as part of the trial screening (most recent metastatic site biopsy preferred, but primary prostate biopsy allowed if metastatic biopsy is not available or inadequate. A new biopsy is not required for enrollment in the trial as long as sufficient archival tissue is available). Due to significant variability between tests, results from an existing targeted next-generation exome sequencing test may not be used for this trial
  • Progressive disease must be demonstrated at study entry while the patient is on continuous androgen deprivation therapy (ADT) or status post orchiectomy. Progressive disease is defined as one or more of the following criteria: * PSA progression, defined by at least 2 consecutive rising PSA values at a minimum of 1-week intervals with the most recent PSA value being 1.0 ng/mL or higher, if confirmed PSA rise is the only indication of progression. Patients who received an anti-androgen must have PSA progression after withdrawal of anti-androgen therapy * Radiographic progression per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for soft tissue lesions * Bone metastasis progression per Prostate Cancer Working Group 3 (PCWG3) criteria for bone lesions
  • Measurable or non-measurable metastatic disease
  • No prior therapy for metastatic castration-resistant prostate cancer, defined as a treatment given for prostate cancer with radiographically-detectable metastasis and a serum testosterone level less than 50 ng/dl (1.73 nmol/L) at the time of pre-registration
  • >= 2 weeks or 5 half-lives (whichever is longer) since prior therapy with flutamide, dutasteride, bicalutamide, niltamide, finasteride, aminoglutethimide, estrogens, cytoproterone, chemotherapy, abiraterone, apalutamide, or darolutamide
  • >= 4 weeks or 5 half-lives (whichever is longer) since any prior investigational therapy
  • >= 4 weeks since a major surgery or radiation
  • No prior therapy with enzalutamide, rucaparib or any other PARP inhibitor, or platinum chemotherapy
  • Prior docetaxel and/or novel anti-androgen use is allowed only if given in the hormone-sensitive disease setting
  • Patient must have discontinued all previous treatments for cancer (except ADT and bone anti-responsive therapies such as denosumab or zoledronic acid) and must have recovered from all acute side effects of prior therapy or surgical procedures to =< grade 1 or baseline prior to randomization, with the exception of fatigue, alopecia or peripheral neuropathy
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Absolute neutrophil count (ANC) >= 1,500/mm^3
  • Platelet count >= 100,000/mm^3
  • Hemoglobin >= 10 g/dL
  • Serum testosterone =< 50 ng/dl (=< 1.73 nmol/L)
  • Serum creatinine =< 1.5 x upper limit of normal (ULN)
  • Total bilirubin =< 1.5 x upper limit of normal (ULN)
  • Aspartate transaminase (AST)/alanine transferase (ALT) =< 2.5 x upper limit of normal (ULN)
  • No clinically suspected central nervous system (CNS) (leptomeningeal or parenchymal) metastases. Patients with a history of CNS metastasis(s) will be allowed as long (1) as the metastatic site(s) were adequately treated as demonstrated by clinical and radiographic improvement, AND (2) the patient has recovered from the intervention (no residual adverse events > Common Terminology Criteria for Adverse Events [CTCAE] grade 1), AND (3) the patient has remained without occurrence of new or worsening CNS symptoms for a period of 28 days prior to pre-registration
  • No known or suspected history of cytopenia (low white blood cell [WBC], hemoglobin or platelet count) of greater than 3 months duration with an unknown cause, myelodysplastic syndrome, or hematologic malignancies
  • No blood product transfusion, granulocyte/granulocyte-macrophage-colony stimulating factor (G-CSF/GM-CSF), or erythropoietin/thrombopoietin use within 14 days of pre-registration
  • No history of syncope of cardiovascular etiology, uncontrolled cardiac arrhythmia, history of Mobitz II second degree or third degree heart block without a permanent pacemaker in place, myocardial ischemia or infarction, severe or unstable angina, New York Heart Association (NYHA) class II to IV heart failure, or stroke/transient ischemic attack (TIA) within 3 months prior to pre-registration on A031902
  • No history of seizure or any condition that may increase the patient’s seizure risk (e.g., prior cortical stroke, significant brain trauma) within 2 years prior to pre-registration on A031902
  • No clinically active or chronic liver disease resulting in moderate/severe hepatic impairment (Child-Pugh class B or C), ascites, coagulopathy or bleeding due to liver dysfunction
  • No clinical, laboratory or radiographic evidence of an active bacterial, fungal, or viral infection requiring treatment at the time of pre-registration
  • No planned palliative procedures for alleviation of bone pain such as radiation therapy or surgery
  • No untreated spinal cord compression or evidence of spinal metastases with a risk of impending fracture or spinal cord compression
  • No known or suspected contraindications or hypersensitivity to enzalutamide, rucaparib, or to any of the excipients
  • No known or suspected gastrointestinal disorder affecting absorption of oral medications
  • No prior malignancy for which the last treatment was given within the past 2 years prior to pre-registration on A031902, or any active concurrent malignancy with the exception of non-melanomatous localized skin cancers (such as squamous or basal cell carcinoma of the skin)
  • Any concomitant medications that are strong inhibitors of CYP2C8 or inducers of CYP3A4 cytochrome enzymes must be discontinued prior to registration. Dose adjustments per Food and Drug Administration (FDA) label or clinical judgement should be considered for any concomitant medications that are moderate inhibitors of CYP2C8 or inducers of CYP3A4 cytochrome enzymes
  • Any concomitant medications that are substrates of CYP3A4, CYP2C9 and CYP2C8 cytochrome enzymes should be monitored closely per clinical judgement of the treating physician
  • Men of reproductive potential should agree to use an appropriate method of birth control and not donate semen while taking rucaparib/placebo and for 6 months following the last dose of rucaparib/placebo due to the teratogenic potential of the therapy utilized in this trial. Appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives or double barrier method (diaphragm plus condom)

Exclusion Criterea

  • Psychiatric illness which would prevent the patient from giving informed consent
  • Medical condition such as uncontrolled infection (including human immunodeficiency virus [HIV]), uncontrolled diabetes mellitus or cardiac disease which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient
  • Patients with a “currently active” second malignancy other than non-melanoma skin cancers or cervical carcinoma in situ. Patients are not considered to have a “currently active” malignancy if they have completed therapy and are free of disease for >= 3 years
  • Patients who cannot swallow oral formulations of the agents

Participating Clinics

OptumCare Cancer Care at Charleston

2300 West Charleston Boulevard
Las Vegas, NV 89102


OptumCare Cancer Care at Fort Apache

6190 South Fort Apache Road
Las Vegas, NV 89148


Valley Medical Center

400 South 43rd Street
Renton, WA 98055